GOSS - Gossamer Bio, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

GOSS

GOSSAMER BIO, INC.

NASDAQ

$10.18

▼ DOWN 5.57% (-0.60)

KEY STATISTICS

Market Cap$62.02 M

52w High$309.60

52w Low$9.10

Dividend Yield—

Frequency—

P/E-14.54

Volume280.27K

Shares Out.6.11M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Faheem Hasnain

COMPENSATION 2026

Salary$649,649

Stock Awards$0

Incentive Plan Pay$254,800

All Other Comp.$4,000

Total$2,300,455

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 8, 2019

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

162

PRICE TARGET

Target High$9.00

Target Low$0.30

Target Median$3.00

Target Consensus$3.47

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$10.67M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-09-11	Reverse	1:80

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

100.00%

HOLDERS

264

TOP 8 OF 264 · RANKED BY POSITION SIZE

Nea Management Company, LLC

Octagon Capital Advisors LP

Aqr Capital Management LLC

Arch Venture Management, LLC

8.1M sh

$24.97M

Samsara Biocapital, LLC

7.2M sh

$22.39M

PRICE

$10.18 ▼ DOWN 5.57% (−$0.60)

OVERLAYS

About Gossamer Bio, Inc.

https://www.gossamerbio.com ↗

Gossamer Bio, Inc. is a San Diego-based clinical-stage biopharmaceutical company developing therapeutics in immunology, inflammation, and oncology, including inhaled and oral small molecules for pulmonary hypertension, IBD, CNS lymphoma, and multi...

INDUSTRY

Biotechnology

A PRODUCT GOSSAMER BIO, INC. IS KNOWN FOR

Seralutinib

Seralutinib, Gossamer Bio's lead Phase 3 inhaled drug, is being developed to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

COMPETITORS

COMPETITOR

Gossamer Bio in 2025

SENTIMENT: + POSITIVE

ANALYST CALL · SEPTEMBER 2025

Gossamer Bio Stock Surges Following UBS Upgrade and Increased Price Target

In September 2025, Gossamer Bio's stock experienced a significant increase, with reports of a surge up to 17.7%. This movement was largely attributed to an analyst upgrade from UBS on September 10, 2025, which changed the stock's rating from "Neutral" to "Buy" and dramatically raised the price target to $9. This upgrade, coupled with the company's presentations at several investor conferences during the month, generated considerable positive investor interest and media attention.

ACQUISITION · SEPTEMBER 2025 · ANNOUNCED

Gossamer Bio Secures Option to Acquire Respira Therapeutics, Expanding its Pulmonary Hypertension Franchise

Gossamer Bio entered into a strategic option agreement to acquire Respira Therapeutics and its lead product candidate, RT234, an inhaled, as-needed treatment for pulmonary hypertension. This move is designed to complement Gossamer's lead asset, seralutinib, and build a comprehensive commercial portfolio for patients with pulmonary hypertension.